# Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

> **NCT04144179** · PHASE1 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 150 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 1
- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 2
- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 3
- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 4
- **BIOLOGICAL:** Quadrivalent RIV with 2018-2019 NH H3 strain

## Key facts

- **NCT ID:** NCT04144179
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-06
- **Primary completion:** 2020-02-24
- **Final completion:** 2020-02-24
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144179, "Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04144179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*